References
- NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Esophageal and esophagogastric junction cancers, version 1. 2019. [cited 2019 Jan 15]. Available at:
https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf - Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v50-7. doi: 10.1093/ annonc/mdw329
- Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7. doi: 10.1001/ jama.281.17.1623
- van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84. doi: 10.1056/NEJMoa1112088
- Jeene PM, van Laarhoven HWM, Hulshof MCCM. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Best Pract Res Clin Gastroenterol 2018; 36-37: 53-9. doi: 10.1016/j.bpg.2018.11.011
- Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-8. doi: 10.1016/S1470-2045(15)00040-6
- Czito BG, DeNittis AS, Palta M. Esophageal Cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Principles and practice of radiation oncology 6th edition. Philadelphia: Lippincott Williams&Wilkins; 2013. p. 995-1023.
- Adebahr S, Schimek-Jasch T, Nestle U, Brunner TB. Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Pract Res Clin Gastroenterol 2016; 30: 565-80. doi: 10.1016/j.bpg.2016.07.003
- Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. [cited 2019 Jan 15]. Available at:
https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf - Guidelines for the treatment of esophageal and esophagogastric junction cancers. [Slovenian]. Anderluh F, But Hadžić J, Crnjac A, Gačevski G, Hlebanja Z, Jeromen A, et al, editors. [cited 2019 Jan 15]. Available at:
https://www.onko-i.si/fileadmin/user_upload/Smernice_za_zdravljenje_raka_poziralnika_in_EGS_splet.pdf - Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, et al. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer. Outcomes and patterns of failure. Strahlentherapie Oncol 2018; 194: 116-24. doi: 10.1007/s00066-017-1211-0
- Jordan T, Mastnak DM, Palamar N, Kozjek NR. Nutritional therapy for patients with esophageal cancer. Nutr Cancer 2018; 70: 23-9. doi: 10.1080/01635581.2017.1374417
- Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9201. J Clin Oncol 2007; 25: 1160-8. doi: 10.1200/JCO.2005.04.7118
- Tomasello G, Ghidini M, Barni S, Passalacqua R, Petrelli F. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. Expert Rev Clin Pharmacol 2017; 10: 649-60. doi: 10.1080/17512433.2017.1313112
- Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res 2017; 10: 13-21. doi: 10.2147/CMAR.S144687
- Li XA, Chibani O, Greenwald B, Suntharalingam M. Radiotherapy dose perturbation of metallic esophageal stents. Int J Radiat Oncol Biol Phys 2002; 54: 1276-85. doi: 10.1016/S0360-3016(02)03803-8
- Stahl M, Stuschke M, Lehkmann N, Meyer H-J, Walz MK, Seeber S, et.al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-7. doi: 10.1200/JCO.2005.00.034
- Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74. doi: 10.1200/ JCO.2002.20.5.1167
- Versteijne F, van Laarhoven HWM, van Hooft JE, van OS RM, Geijsen ED, van Berge Henegouwen MI, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus 2015; 28: 453-9. doi: 10.1111/dote.12215
- Teoh AYB, Chiu PWY, Yeung WK, Liu SYW, Wong SKH, Ng EKW. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013; 24: 165-71. doi: 10.1093/annonc/mds206
- Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 2018; 41: 210-5. doi: 10.1016/j.asjsur.2016.10.005
- Domper Arnal MJ, Ferrandez Arenas A, Lanas Arbeloa A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol 2015; 21: 7933-43. doi: 10.3748/wjg.v21.i26.7933